<DOC>
	<DOCNO>NCT01478685</DOCNO>
	<brief_summary>The purpose study evaluate safety define Maximal Tolerated Dose ( MTD ) Maximal Administered Dose ( MAD ) oral azacitidine single agent combination carboplatin ( CBDCA ) paclitaxel protein bound particle ( ABI-007 , ABX ) subject relapse refractory solid tumor .</brief_summary>
	<brief_title>A Phase 1 Study CC-486 Single Agent Combination With Carboplatin ABI-007 Subjects With Relapsed Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<mesh_term>Fallopian Tube Neoplasms</mesh_term>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Pancreatic Ductal</mesh_term>
	<mesh_term>Carcinoma , Transitional Cell</mesh_term>
	<mesh_term>Tumor Virus Infections</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<criteria>1 . Men woman , 18 year old time signing Informed Consent Document ( ICD ) . 2 . Understand voluntarily sign ICD prior studyrelated assessment procedure conduct . 3 . Able adhere study visit schedule protocol requirement . 4 . With histological cytological confirmation advance unresectable solid tumor , include progress ( able tolerate ) standard anticancer therapy , effective therapy exists , decline standard therapy . 5 . Consent screen tumor biopsy ( accessible tumor appropriate [ optional Part 1 , mandatory Part 2 ] ) . 6 . Eastern Cooperative Oncology Group ( ECOG ) Performance Status ≤ 2 . 7 . The following laboratory value : Absolute neutrophil count ( ANC ) ≥ 1.5 X 10^9/L Hemoglobin ( Hgb ) ≥90 g/L Platelets ( plt ) ≥ 100 x 10^9/L Potassium within normal range , correctable supplement ; AST ALT ≤2.5 x Upper Limit Normal ( ULN ) ≤5.0 x ULN liver tumor present ; Serum total bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN , 24hr clearance ≥ 60ml/min ; Negative serum pregnancy test within 7 day start study treatment female childbearing potential ( FCBP ) 8 . Females childbearing potential { define sexually mature woman undergone hysterectomy ( surgical removal uterus ) bilateral oophorectomy ( surgical removal ovary ) , naturally postmenopausal least 24 consecutive month ( i.e. , menses time precede 24 consecutive month } must agree use physician approve contraceptive method ( oral , injectable , implantable hormonal contraceptive ; tubal ligation ; intrauterine device ; barrier contraceptive spermicide ; vasectomized partner ) oral azacitidine 3 month follow last dose study medication ; negative serum pregnancy test screen 9 . Male subject female partner childbearing potential must agree use physicianapproved contraceptive method throughout course study avoid father child course study 6 month follow last dose oral azacitidine . The criterion addition supersede Part 1 inclusion criterion : 1 . With histological cytological confirmation relapse refractory advance unresectable solid tumor list Arm , include progress unable tolerate standard anticancer therapy . Arm A : CC486 plus CBDCA : Relapsed refractory urothelial carcinoma bladder , renal pelvis , ureter , urethra ( mixed histology permit provided component urothelial carcinoma present ) Epithelial ovarian , fallopian tube , primary peritoneal carcinoma Arm B : CC486 plus ABI007 : NSCLC Pancreatic carcinoma Arm C : CC486 single agent : Virallyassociated tumor tumor type know driven EpsteinBarr Virus ( EBV ) , Human Papilloma Virus ( HPV ) , Merkel cell carcinoma skin ( MC Polomavirus ) Nasopharyngeal carcinoma ( minimum 5 subject ) Cervical carcinoma Anal carcinoma Merkel cell carcinoma ( MCC ) Note : Hepatitis B virus ( HBV ) Hepatitis C virus ( HCV ) associate tumor ( hepatocellular cancer ) eligible . Note : Head neck squamous cell cancer ( HNSCC ) must HPVpositive status document eligible 2 . Subjects document liver metastasis must serum albumin ≥ 3 g/dL ; 3 . Sites disease ( primary metastatic ) , opinion investigator , accessible biopsy without undue risk subject 4 . Consent tumor biopsy screening ( prior first dose CC486 ) Cycle 1 Day 15 . 5 . Measurable disease accord RECIST v1.1 . 1 . Any significant medical condition , laboratory abnormality , psychiatric illness would prevent subject participate study . 2 . Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study . 3 . Any condition confound ability interpret data study . 4 . Symptomatic central nervous system metastasis . Subjects brain metastases previously treat stable 6 week allow . 5 . Known acute chronic pancreatitis . 6 . Any peripheral neuropathy ≥ NCI CTCAE grade 2 . 7 . Persistent diarrhea malabsorption ≥ NCI CTCAE grade 2 , despite medical management . 8 . Impaired ability swallow oral medication . 9 . Unstable angina , significant cardiac arrythmia , New York Heart Association ( NYHA ) class 3 4 congestive heart failure . 10 . Prior systemic cancerdirected treatment investigational modality ≤ 5 half live 4 week , whichever short , prior start study drug recover side effect therapy . ( except alopecia ) . 11 . Major surgery ≤ 2 week prior start study drug recover side effect therapy . 12 . Pregnant breast feeding . 13 . Known Human Immunodeficiency Virus ( HIV ) infection . 14 . Known chronic hepatitis B C virus ( HBV/HCV ) infection , unless comorbidity subject HCV . 15 . Liver metastases serum albumin &lt; 3 g/dL . 16 . Other prior cancer within previous 5 year except adequately treat situ carcinoma cervix , basal , squamous carcinoma skin . 17 . Subjects &gt; 4 prior systemic chemotherapy regimen require approval Celgene Medical Monitor prior enrollment . A regimen define &gt; /= 2 cycle systemic anticancer therapy contain 1 agent follow class : topoisomerase 1 2 inhibitor , platinum salt , alkylating agent , tubulin inhibitor , antimetabolites vinca alkaloid .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Relapsed Refractory Solid Tumors</keyword>
</DOC>